GB1326528A - Method of contraception and compositions used therein - Google Patents
Method of contraception and compositions used thereinInfo
- Publication number
- GB1326528A GB1326528A GB4376471A GB4376471A GB1326528A GB 1326528 A GB1326528 A GB 1326528A GB 4376471 A GB4376471 A GB 4376471A GB 4376471 A GB4376471 A GB 4376471A GB 1326528 A GB1326528 A GB 1326528A
- Authority
- GB
- United Kingdom
- Prior art keywords
- phenoxy
- acetate
- methoxy
- pyrrolidine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1326528 Contraceptive RICHARDSONMERRELL INC 20 Sept 1971 [5 Oct 1970] 43764/71 Heading A5B Contraception in human females is achieved by the administration of a progestagen (A) and an estrogen antagonising compound (B). They may be administered daily or the compound (A) may be administered at least during some of the days 5 to 28 of the menstrual cycle, compound (B) being administered on at least some of days 10 to 25. Suitable progestagens are: chlormadinone, megestrol acetate, melengestrol acetate, norethindrone and its acetate, norgestrel and its acetate, quingestanol and its acetate, desoxynorethindrone and ethynodiol diacetate. The estrogen antagonising agent is selected from the following (the quantities in parenthesis being the daily dose range): cisclomiphene (0.5-50 mg), 2-[p-(p-methoxy-α- phenylphenethyl) phenoxy]-triethylamine (10- 1000 mg), 1-[2-[p-(α-[p-methoxyphenyl]-#-nitrostyryl) phenoxy] ethyl] pyrrolidine (1 to 100 mg), 2[p-(1, 2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine (1-100 mg), 2-[p-(1, 2- diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine-antiestrogenic isomer (1-100 mg), 2-'[p-(6-methoxy-2-phenylindene - 3 - yl) phenoxy] ethyl pyrrolidine (2-200 mg), dl-13-ethylhydro- 6 -methoxy- 2 -phenyl-1-naphthyl) phenoxy] ethyl] pyrrolidine (2-200 mg), dl-3-ethylgona-1, 3, 5 (10)-triene-3, 16α, 17# triol (1- 100 mg) and compounds of the formula: wherein R is H or COCH 3 and R' is H or CH 3 , and equivalent quantities of pharmaceutically acceptable salts of the base compounds.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7825870A | 1970-10-05 | 1970-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1326528A true GB1326528A (en) | 1973-08-15 |
Family
ID=22142910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB4376471A Expired GB1326528A (en) | 1970-10-05 | 1971-09-20 | Method of contraception and compositions used therein |
Country Status (8)
Country | Link |
---|---|
AU (1) | AU462092B2 (en) |
BE (1) | BE773518A (en) |
CA (1) | CA963806A (en) |
DE (1) | DE2149281A1 (en) |
FR (1) | FR2110233B1 (en) |
GB (1) | GB1326528A (en) |
IL (1) | IL37772A (en) |
ZA (1) | ZA716118B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2129297A (en) * | 1976-09-01 | 1984-05-16 | Bristol Myers Co | Post-mastectomy treatment dosage units containing megestrol acetate |
WO1999024027A2 (en) * | 1997-11-06 | 1999-05-20 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
US20210292272A1 (en) * | 2020-03-20 | 2021-09-23 | Apotex Inc. | Salts of Zuclomiphene |
-
1971
- 1971-09-13 ZA ZA716118A patent/ZA716118B/en unknown
- 1971-09-20 GB GB4376471A patent/GB1326528A/en not_active Expired
- 1971-09-23 IL IL37772A patent/IL37772A/en unknown
- 1971-09-30 AU AU34060/71A patent/AU462092B2/en not_active Expired
- 1971-09-30 CA CA124,085A patent/CA963806A/en not_active Expired
- 1971-10-02 DE DE19712149281 patent/DE2149281A1/en active Pending
- 1971-10-05 BE BE773518A patent/BE773518A/en unknown
- 1971-10-05 FR FR7135858A patent/FR2110233B1/fr not_active Expired
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2129297A (en) * | 1976-09-01 | 1984-05-16 | Bristol Myers Co | Post-mastectomy treatment dosage units containing megestrol acetate |
WO1999024027A2 (en) * | 1997-11-06 | 1999-05-20 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
WO1999024027A3 (en) * | 1997-11-06 | 1999-07-15 | American Home Prod | Anti-estrogen plus progestin containing oral contraceptives |
JP2001522798A (en) * | 1997-11-06 | 2001-11-20 | アメリカン・ホーム・プロダクツ・コーポレイション | Oral contraceptive containing antiestrogen and progestin |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
AU760540B2 (en) * | 1997-11-06 | 2003-05-15 | Wyeth | Anti-estrogen plus progestin containing oral contraceptives |
US20210292272A1 (en) * | 2020-03-20 | 2021-09-23 | Apotex Inc. | Salts of Zuclomiphene |
Also Published As
Publication number | Publication date |
---|---|
AU462092B2 (en) | 1975-06-12 |
FR2110233B1 (en) | 1974-09-06 |
CA963806A (en) | 1975-03-04 |
AU3406071A (en) | 1973-04-05 |
IL37772A (en) | 1975-04-25 |
ZA716118B (en) | 1972-05-31 |
BE773518A (en) | 1972-01-31 |
FR2110233A1 (en) | 1972-06-02 |
DE2149281A1 (en) | 1972-04-06 |
IL37772A0 (en) | 1971-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3969502A (en) | Method for contraception by the administration of sequential contraceptive preparations | |
US5262408A (en) | Low estrogen oral contraceptives | |
US3932635A (en) | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | |
DE69710896T2 (en) | PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES | |
EP0397823B1 (en) | Contraception system and method | |
US3942641A (en) | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | |
EP0655916B1 (en) | Transdermal application agent containing 3-keto-desogestrel | |
US4145416A (en) | Novel agents and novel methods for treatment of climacteric disturbances | |
DE69117902T2 (en) | Progestogen as the only contraceptive | |
AU7537987A (en) | Combination dosage form for pre-menopausal women | |
NZ278058A (en) | 23 or 24 day contraceptive formulation comprising both an estrogen and a gestagen, administered in constant amounts throughout the 23 or 24 days | |
SE7416039L (en) | ||
US3795734A (en) | Cyclic regimen of hormone administration for contraception | |
US3755573A (en) | Fertility control empoying quinestrol and quingestanol acetate | |
DE19549264A1 (en) | Contraception procedure and kit | |
GB1459675A (en) | Method for the prevention of conception | |
GB1343595A (en) | Oral contraceptive combination | |
GB1326528A (en) | Method of contraception and compositions used therein | |
GB1462893A (en) | Method for fertile breeding control in female bovine | |
GB1285371A (en) | Improvements in or relating to therapeutic methods using prostaglandins | |
GB1152679A (en) | Pharmaceutical and Veterinary Preparations | |
USRE35724E (en) | Contraception system and method | |
GB1488995A (en) | Compositions containing anti-androgenic compounds | |
GB2165750A (en) | Contraceptive synergistic association | |
IE34308L (en) | 11ß, 13ß-DIALKYLGONA-1,3,5(10)-TRIEN-3-OL 3-CYCLOALKYL¹ETHERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PLNP | Patent lapsed through nonpayment of renewal fees |